Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF
5 May 2025
No Comments
AUSTIN, Texas, May 1, 2025 (PR Newswire) —Rein Therapeutics (“Rein”) (NASDAQ: RNTX), a biopharmaceutical
